PROF

Profound Medical Corp. develops and markets customizable, incision-free therapies for the ablation of diseased tissue. Headquartered in Mississauga, Ontario, the company commercializes two proprietary platforms: TULSA-PRO and Sonalleve. TULSA-PRO (Transurethral Ultrasound Ablation) combines real-time MRI imaging with directional thermal ultrasound to treat prostate disease, including prostate cancer and benign prostatic hyperplasia. The system received FDA approval in 2019 and has CE Mark approval in Europe. Sonalleve is an MRI-guided focused ultrasound platform designed for the ablation of uterine fibroids, certain bone metastases, and other tumor types. Profound Medical operates through direct sales in the United States and Germany, while utilizing distributors in select international markets. The company manufactures its devices through third-party contractors and maintains clinical and technical support teams to service its installed base. As of recent reports, Profound Medical has placed systems in hospitals and treatment centers across North America and Europe, focusing on building procedure volume and expanding clinical indications. The company continues to invest in clinical studies to support regulatory approvals and reimbursement pathways in key markets. Profound Medical trades on the Toronto Stock Exchange under the symbol PRN and on NASDAQ under the symbol PROF.